Trial Profile
An Open Label Study to Assess the Safety and Efficacy of COR-003 (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs Levoketoconazole (Primary)
- Indications Cushing syndrome
- Focus Registrational; Therapeutic Use
- Acronyms SONICS
- Sponsors Strongbridge Biopharma; Xeris Biopharma Holdings
- 01 Nov 2022 Results published in the Media Release
- 01 Nov 2022 According to a Xeris Biopharma Holdings media release, european Journal of Endocrinology published the extended evaluation results of this study.
- 30 Dec 2021 According to a Xeris Biopharma Holdings media release, the FDA decision follows successful completion of acquisition of Strongbridge Biopharma on October 5, 2021.